newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

  • Praxis Precision Medicines will report Q2 2026 financial results & provide a corporate update before market open on Thursday, August 6, 2026.
  • The company will host a conference call & live webcast on August 6, 2026, at 8:30 am ET, accessible via registration link or the Investors + Media section of www.praxismedicines.com.
  • A replay of the earnings webcast will be available on the company website for approximately 90 days after the event.
  • Praxis is a CNS precision neuroscience biopharmaceutical company utilizing its Cerebrum™ small molecule & Solidus™ ASO platforms to develop therapies for neuronal excitation-inhibition imbalance disorders.
  • The company maintains a diversified CNS portfolio with four late-stage product candidates across movement disorders & epilepsy.
  • Investor inquiries can be directed to investors@praxismedicines.com or 857-702-9452.
  • Media inquiries can be directed to Dan Ferry at LifeSci Advisors via Daniel@lifesciadvisors.com or 617-430-7576.